Paul-Henry Schmelck
Keine laufenden Positionen mehr
Profil
Dr. Paul-Henry Schmelck, MD, is Directeur de Participations at OTC Asset Management SA in France.
He received his doctorate degree from Université Paris, and a graduate degree from Université Paris.
Ehemalige bekannte Positionen von Paul-Henry Schmelck
| Unternehmen | Position | Ende |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Direktor/Vorstandsmitglied | 08.03.2010 |
Apicap SAS
 Apicap SAS Investment ManagersFinance Apicap SAS is a Venture Capital firm, a subsidiary of OTC Holding SAS founded in 2001. Apicap SAS is headquartered in Paris. | Private Equity Investor | 01.10.2009 |
PrimeBioTech
 PrimeBioTech Medical DistributorsDistribution Services PrimeBioTech develops therapeutic products based on gene therapy technologies. The private company is based in Paris, France. | Präsident | 01.01.2004 |
| NANOBIOTIX | Corporate Officer/Principal | - |
| NEOVACS | Direktor/Vorstandsmitglied | - |
Ausbildung von Paul-Henry Schmelck
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SANOFI | Health Technology |
| NEOVACS | Health Technology |
| NANOBIOTIX | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Apicap SAS
Apicap SAS Investment ManagersFinance Apicap SAS is a Venture Capital firm, a subsidiary of OTC Holding SAS founded in 2001. Apicap SAS is headquartered in Paris. | Finance |
PrimeBioTech
PrimeBioTech Medical DistributorsDistribution Services PrimeBioTech develops therapeutic products based on gene therapy technologies. The private company is based in Paris, France. | Distribution Services |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
